One of the least comfortable facts about GLP-1 medications is what happens when treatment stops: on average, a good share of the lost weight comes back. A phase 3b trial published in Nature Medicine this year asked a practical follow-up question. If someone finishes a course of injectable semaglutide or tirzepatide, can switching to a once-daily oral GLP-1 called orforglipron slow that regain?
The headline answer was yes, compared with placebo. The details are where a reader should slow down.
What the trial did
ATTAIN-MAINTAIN enrolled adults who had just completed SURMOUNT-5, a 72-week trial of semaglutide or tirzepatide in people with obesity and without diabetes. Within 14 days of their last injectable dose, 376 participants were randomly assigned to orforglipron or placebo for 52 weeks: 205 coming off tirzepatide and 171 coming off semaglutide. Orforglipron started at 12 mg and was raised every four weeks toward a maximum of 36 mg as tolerated.
The result that got attention: among people who had reached a weight plateau, those who had been on tirzepatide kept about 75% of their prior weight loss on orforglipron versus 49% on placebo. For the semaglutide group it was about 79% versus 38%. The share who held on to at least 80% of their loss was 43.7% versus 16.4% after tirzepatide, and 55% versus about 7% after semaglutide. Improvements in blood sugar and lipid markers were largely preserved too. Treatment was stopped for side effects in roughly 5% to 7% of people on the pill, mostly gastrointestinal complaints such as nausea, diarrhea, vomiting, and constipation.
What it does not establish
The comparison is against placebo, not against staying on the injection. There was no arm that continued semaglutide or tirzepatide. So the trial shows that an active drug beat nothing, which is a fairly low bar after a drug has been withdrawn. It cannot say whether the pill holds weight as well as simply continuing the injectable.
The placebo arm thinned out. Anyone on placebo who regained at least half of their earlier loss could be switched to orforglipron, and 81 people were. Only 37 people originally assigned to placebo finished the trial without active treatment. After the early weeks, the placebo group is a smaller and increasingly selected set of people, which makes later comparisons harder to read.
A year is short. Weight regain after stopping these medications tends to unfold over a long period, as the Cambridge regain analysis we covered earlier describes. Fifty-two weeks says little about year three.
The sample is narrow. Participants averaged about 49 years old, were roughly 65% women and 74% White, and were mostly recruited in the U.S. All had already completed a 72-week trial, which means they had tolerated the earlier drug and stayed in a study. People who dropped out or stopped early are not represented, and they may be exactly the people who struggle most with maintenance.
Averages are not individual results. Even in the pill arm, a quarter or so of the prior loss was typically lost again in the tirzepatide cohort, and many participants fell short of the 80% mark. How any one person responds depends on factors a trial average cannot predict.
Who paid matters. The coverage we reviewed did not state a funding source. The drug is a Lilly product, and so is tirzepatide, so readers should check the paper’s disclosures before treating the framing as neutral.
The part that applies to compounded medications
This trial studied manufactured products from a regulated clinical program, and orforglipron is a manufactured product from a pharmaceutical developer, not a compounded preparation. This post takes no position on its regulatory status. None of it transfers to a compounded medication, which is prepared by a pharmacy for an individual patient, is not FDA-approved, and has not been tested in trials like this one. Likewise, the findings say nothing about how any specific injectable dose would behave once stopped.
What a reader can reasonably take from it
The useful signal is modest and honest: weight regain after stopping is common enough that researchers are testing structured ways to manage it, and a daily maintenance pill is one candidate being studied. Whether that becomes a real option depends on longer trials, head-to-head comparisons, and approval decisions that haven’t been made by a headline.
Meanwhile, the practical point for anyone on treatment is unchanged. Decisions about dose, duration, and what comes after belong in a conversation with a licensed provider, informed by your own history. How the process works and our FAQ lay out what that looks like with NoBsRx.
This post is general information, not medical advice. It does not describe a benefit of any NoBsRx program, and it is not a claim that any medication prevents weight regain. Compounded medications are not FDA-approved. Treatment is never guaranteed — eligibility and every treatment decision are made by independent licensed providers based on an individual clinical assessment, and availability varies by state. Do not start, stop, or change any treatment based on an article. Talk to a licensed clinician before making changes to your care.